RxDoctor Payments Data

Haritha Arikatla, MD

Internal Medicine · Braselton, GANPI 1255437075

Payments from drug & device makers

$2,764in general payments, 2019–2025

Across 153 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$549
  • AbbVie$314
  • Amgen$283
  • Pfizer$243
  • Lilly USA, LLC$235
  • Astellas Pharma US Inc$226
  • plus $915 from 19 others

What the payments were for

  • Food & beverage$2,764100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,764 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$182,194
Medicare patients
441
Services billed
3,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide95$138,221
FarxigaDapagliflozin Propanediol85$80,216
OzempicSemaglutide74$79,957
JardianceEmpagliflozin68$76,175
TrulicityDulaglutide31$36,991
JanuviaSitagliptin Phosphate24$30,094
TradjentaLinagliptin20$22,761
MyrbetriqMirabegron27$15,299
ShingrixVaricella-Zoster Ge/As01b/Pf65$14,294
EliquisApixaban18$14,159
ArexvyRsvpref3 Antigen/As01e/Pf37$11,550
RybelsusSemaglutide11$10,513
Tresiba Flextouch U-100Insulin Degludec11$10,189
Emgality PenGalcanezumab-Gnlm12$8,321
Duloxetine Hcl273$6,489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$235$175,212126 claims
Boehringer IngelheimJardiance, Tradjenta$35$98,93688 claims
Novo NordiskOzempic, Rybelsus$549$90,46985 claims
AstraZenecaFarxiga$146$80,21685 claims
GSKShingrix, Arexvy, Breo Ellipta$118$31,881117 claims
Astellas Pharma US IncMyrbetriq$226$15,29927 claims
PfizerEliquis$243$14,15918 claims
AbbVieSynthroid$314$4,61254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Braselton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →